Immatics N.V. (IMTX) News

Immatics N.V. (IMTX): $12.95

0.17 (-1.30%)

POWR Rating

Component Grades








Add IMTX to Watchlist
Sign Up

Industry: Biotech




#83 of 354

in industry

Filter IMTX News Items

IMTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest IMTX News From Around the Web

Below are the latest news stories about IMMATICS NV that investors may wish to consider to help them evaluate IMTX as an investment opportunity.

Levicept Appoints Eliot Forster as CEO

Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty y

Yahoo | November 30, 2023

Immatics Announces Third Quarter 2023 Financial Results and Business Update

ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR) not reached at median follow-up of 14.4 months including responses ongoing at >15 months after infusion; IMA203 GEN1 continues to be well tolerated; company is targeting registration-enabling Phase 2 trial in melanoma to commence in 2024; update on the clinical development plan in 1Q 2024First clinical data on ACTengine® IMA203CD8 GEN2 TCR-T targeting PRAME de

Yahoo | November 14, 2023

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the International Congress of the Society for Melanoma Research today, November 8 IMA203 GEN1 TCR cell therapy targeting PRAME – update on Phase 1a and Cohort A Continues to be well tolerated50% confirmed objective response rate (cORR) in melanoma patients treated at recommended Phase 2 dose; durability with some ongoing responses at >15 months and me

Yahoo | November 8, 2023

Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | November 2, 2023

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer typesRegulatory activities underway with an initial focus on a registration-directed trial in melanoma as step one to leverage the full breadth of PRAME Houston, Texas and Tuebingen, Germany, October 24, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and develop

Yahoo | October 24, 2023

Immatics N.V. (NASDAQ:IMTX) is definitely on the radar of institutional investors who own 47% of the company

Key Insights Significantly high institutional ownership implies Immatics' stock price is sensitive to their trading...

Yahoo | September 23, 2023

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

Appointment effective as of September 14, 2023;Zeev Bronfeld to retire from the Board of Directors

Yahoo | September 12, 2023

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Moderna, Inc. (NASDAQ:MRNA, "Moderna") and Immatics N.V. (NASDAQ:IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need.

Yahoo | September 11, 2023

Those who invested in Immatics (NASDAQ:IMTX) three years ago are up 27%

By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual...

Yahoo | August 27, 2023

Immatics Announces Second Quarter 2023 Financial Results and Business Update

Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAMEACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on 11 heavily pre-treated patients in Phase 1b dose expansion Cohort A with median duration of response not reached at a median follow-up time of 8.5 months at data cut-off; next update in 4Q 2023Bristol Myers Squibb exercised first opt-in into

Yahoo | August 17, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!